enVVeno Medical (NVNO) Expected to Announce Quarterly Earnings on Thursday

enVVeno Medical (NASDAQ:NVNO) is expected to post its results before the market opens on Thursday, February 26th. Analysts expect enVVeno Medical to post earnings of ($9.80) per share for the quarter.

enVVeno Medical Stock Performance

Shares of NVNO stock traded up $1.71 during trading hours on Friday, hitting $11.70. 37,377 shares of the company were exchanged, compared to its average volume of 25,116. The stock has a market capitalization of $7.72 million, a price-to-earnings ratio of -0.31 and a beta of 1.07. enVVeno Medical has a one year low of $8.67 and a one year high of $196.70. The business’s 50-day simple moving average is $11.12 and its two-hundred day simple moving average is $31.66.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of enVVeno Medical in a research report on Monday, December 29th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, enVVeno Medical has a consensus rating of “Reduce”.

Institutional Trading of enVVeno Medical

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Jane Street Group LLC bought a new stake in shares of enVVeno Medical in the 2nd quarter worth approximately $51,000. Creative Planning acquired a new stake in enVVeno Medical in the second quarter worth $54,000. Geode Capital Management LLC lifted its stake in enVVeno Medical by 1.1% in the second quarter. Geode Capital Management LLC now owns 199,509 shares of the company’s stock valued at $796,000 after buying an additional 2,211 shares during the last quarter. Finally, Perceptive Advisors LLC bought a new stake in enVVeno Medical in the second quarter valued at $5,127,000. 34.71% of the stock is currently owned by institutional investors and hedge funds.

enVVeno Medical Company Profile

enVVeno Medical, Inc is a clinical‐stage medical device company focused on the development and commercialization of subcutaneous vascular access systems for patients requiring repeated or long‐term intravenous therapy. Through its proprietary Freedom® platform, the company aims to offer an implantable alternative to traditional peripherally inserted central catheters (PICCs) and external tunneled catheters, addressing complications such as infection risk, dislodgement and patient discomfort.

The company’s lead product candidate, the Freedom PICC System, consists of a low‐profile, subcutaneous port connected to a flexible catheter designed for peripheral insertion.